trial · primary record
nab-sirolimus
Tumor
| Phase | Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 128 |
| Primary completion | 2024-12-23 |
| Primary endpoint | Overall Response Rate (ORR) |
| Registry ID | NCT05103358 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:41:51.184Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05103358
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Nab-Sirolimus · compound